Seeking Alpha

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
MedPage Today

Second Late-Stage Trial Shows Efficacy of Dupilumab for COPD

Adding dupilumab (Dupixent) to triple therapy reduced exacerbations and improved lung function for chronic obstructive pulmonary disease (COPD) patients with blood eosinophil evidence of type 2 ...
Seeking Alpha

Altesa BioSciences Details Positive Topline Vapendavir Results from Phase 2 Placebo-Controlled Rhinovirus Challenge Study in COPD Patients

Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...
Morningstar

Altesa BioSciences Presents Findings Demonstrating Beneficial Effects of vapendavir for Treating Rhinovirus Infections in COPD Challenge Study

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 Dr. Brett Giroir, Chief Executive ...
Healio

Transcatheter mitral valve repair safe, effective for patients with COPD

Please provide your email address to receive an email when new articles are posted on . The presence of chronic obstructive pulmonary disease is not associated with intra-hospital or 1-year outcomes ...
Nasdaq

Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary ...